Human growth hormone (hGH): biosimilar pricing is not enough, convenience will mandate
- Category: Press Room
- Published on Tuesday, 07 October 2008 10:58
- Hits: 9857
After approval of three biosimilar hGH products, the pipeline is full of next generation hGH products with less frequent injection or non-injectable delivery
Barcelona, Spain | October 7, 2008 | The Business Intelligence firm La Merie S.L. conducted an analysis of the R&D pipeline of human growth hormone (hGH, somatropin). The study revealed that Sandoz (the generic division of Novartis) sells the biogeneric somatropin as Omnitrope at a 25 % discount but only achieved 2007 sales of about US$ 8 mln representing a 0.3 % share of the worldwide hGH market in 2007 of US$ 2.7 bln (published data only). Although 2008 sales of Omnitrope are growing steadily, they can be expected to achieve only about US$ 30 mln (about 1 % of the ww market). The number of mere copycat hGH biosimilars in regulated markets is rather limited to a total of three approved biosimilar versions in the EU and/or US and two other versions in the pipeline of 1st generation somatropin biogenerics. The majority of next generation products attempts to improve frequency of administration or delivery. To reduce frequency of SC injections, slow-release formulations are the clinically most advanced approaches followed by the PEGylated versions of hGH which is the preferred option of the established hGH marketers. Engineering of hGH to prolong half-life is a next generation approach already in early clinical development, but still requires injection. In contrast, non-injectable delivery approaches promise to avoid injection by oral, transdermal or nasal administration with the first projects already in phase I/II clinical trials. These results and more were found in the search conducted by La Merie Business Intelligence. The evaluation can be acquired at La Merie’s online store (www.pipelinereview.com/store ).
Human growth hormone (hGH; somatropin) was the first therapeutic protein for which a biosimilar version was approved in the US and in Europe in 2006. There are numerous manufacturers of hGH in non-regulated markets, but most of them do not produce in a manner allowing approval in regulated markets although these products are frequently consumed by those interested in gaining muscle mass. Manufacturers in non-regulated markets are also investing in development of next generation hGH products and some of them invest in WHO-GMP compliant infrastructure.
About La Merie
La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com.
PipelineReview.com is the News Center and Online Store of La Merie Business Intelligence focused on Research and Development in the Biopharmaceutical Industry. Visitors of PipelineReview.com will find R&D relevant press releases and can receive selected R&D news from one or more of the site’s News Channels. La Merie Daily and La Merie Biologics conveniently bring via e-mail a daily or weekly selection of the most interesting news from biopharmaceutical R&D. For more information visit www.pipelinereview.com.
SOURCE: La Merie